Compare Amylx Pharmaceuticals Inc (AMLX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Prologis Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.66 (market cap $2.64B), while Prologis Inc trades at $139.39 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 50.2× Amylx Pharmaceuticals Inc's market cap, and Prologis Inc pays a 3.07% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PLD | |
|---|---|---|
Market Cap | $2.64B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $24.19 | $149.96 |
52-Week Low | $7.82 | $104.81 |
Enterprise Value | $2.39B | $167.31B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Prologis (PLD) trades at $138.73, down 1.02% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights a major acquisition of SEGRO for $18.8 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show volatility, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.
The outlook is positive due to robust earnings growth and strategic expansion, but risks include rising debt levels and integration challenges from the SEGRO deal. Analysts are bullish with a $159.22 consensus target, suggesting 15% upside, supported by institutional holdings and dividend payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
